** Shares in Laboratorios Rovi ROVI.MC fall 16%, set for their worst day in nearly 15 years, after the Spanish pharmaceutical company said it expected its 2024 EBITDA to come lower than market consensus
** It forecasts its 2024 EBITDA to be between 10% and 15% lower than 2024 EBITDA levels expected by market consensus, due to anticipated lower activity in its contract manufacturing $(CDMO)$ business in Q4
** Rovi also said it maintains its guidance for 2025
** "We expect a negative reaction because the impact on EBITDA is relevant and because it will once again raise doubts about its CDMO business, which today is the most relevant," says Sabadell broker in a note
** The lower demand of Covid-19 vaccines from Moderna MRNA.O, that Rovi manufactures, would be the main reason for the lower activity in Q4, says a Renta 4 analyst
** The company is due to report its full year results on February 25
** Shares at their lowest level since December 2023
(Reporting by Joao Manuel Mauricio)
((JoaoManuel.VicenteMauricio@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.